Search

Displaying results 3061 - 3070 of 10000 in total
  1. Drug

    Tislelizumab

    go.drugbank.com/drugs/DB14922
    ApprovedInvestigational

    [L49439] Tislelizumab was also approved by the FDA on March 14, 2024.[L50346] It has subsequently been approved for additional cancers in the US and EU. [L49349] … [A262919] Tislelizumab is generally well tolerated with manageable and mild-to-moderate adverse effects.

    Categories: Amino Acids, Peptides, and Proteins, Antineoplastic and Immunomodulating Agents
  2. Drug

    Berberine

    go.drugbank.com/drugs/DB04115
    ApprovedInvestigationalWithdrawn

    An alkaloid from Hydrastis canadensis L., Berberidaceae. It is also found in many other plants. … It is relatively toxic parenterally, but has been used orally for various parasitic and fungal infections and as antidiarrheal.

  3. Drug

    Orforglipron

    go.drugbank.com/drugs/DB18964
    ApprovedInvestigational

    [L56123] On April 1, 2026, the US FDA granted approval to orforglipron for use alongside diet and exercise to aid in weight reduction in certain patient populations. … [A275476] Developed to circumvent the adherence barriers and strict administration requirements of peptide-based GLP-1 therapies, its small-molecule structure enables once-daily oral dosing without food

  4. Drug

    Palifermin

    go.drugbank.com/drugs/DB00039
    ApprovedInvestigational

    It is 140 residues long, and is produced using E. coli. Palifermin was granted FDA approval on 15 December 2004.[L17933]

    Categories: Amino Acids, Peptides, and Proteins, Intercellular Signaling Peptides and Proteins
  5. Drug

    Eptifibatide

    go.drugbank.com/drugs/DB00063
    ApprovedInvestigational

    Synthetic cyclic hexapeptide that binds to platelet receptor glycoprotein and inhibits platelet aggregation. … Derived from venom of the Southeastern pygmy rattlesnake (Sistrurus miliarus barbouri), eptifibatide is a cyclic heptapeptide that belongs to the class of arginin-glycin-aspartat-mimetics.

    Categories: Blood and Blood Forming Organs, Amino Acids, Peptides, and ProteinsProducts: EPTİCARD 75MG/100ML İV İNFÜZYON ÇÖZELTİSİ İÇEREN FLAKON, 1 ADET
  6. Drug

    Elagolix

    go.drugbank.com/drugs/DB11979
    ApprovedInvestigational

    Moreover, women who are affected by this condition can suffer for up to six to ten years and visit multiple physicians before receiving a proper diagnosis [A35868, A35869, F801]. … unmet needs of women who are affected by endometriosis, depending on their specific type and severity of endometriosis pain.

    Categories: Pituitary and Hypothalamic Hormones and Analogues, Sex Hormones and Insulins
  7. Drug

    Equine Botulinum Neurotoxin G Immune FAB2

    go.drugbank.com/drugs/DB13899
    Approved

    Equine Botulinum Neurotoxin G Immune FAB2 is composed of a mixture of immune globulin fragments purified from plasma of horses that were previously immunized with botulinum toxin serotype G. … It is intravenously administered for the treatment of symptomatic botulism following documented or suspected exposure to botulinum neurotoxin serotypes G in adults and pediatric patients.

  8. Drug

    Equine Botulinum Neurotoxin D Immune FAB2

    go.drugbank.com/drugs/DB13902
    Approved

    Equine Botulinum Neurotoxin D Immune FAB2 is composed of a mixture of immune globulin fragments purified from plasma of horses that were previously immunized with botulinum toxin serotype D. … It is intravenously administered for the treatment of symptomatic botulism following documented or suspected exposure to botulinum neurotoxin serotypes D in adults and pediatric patients.

  9. Drug

    Lifileucel

    go.drugbank.com/drugs/DB17107
    ApprovedInvestigational

    Lifileucel is a tumour-derived autologous T cell immunotherapy composed of a suspension of tumour-derived T cells from the patient [L50171] which undergo isolation, ex vivo expansion, and activation[A263341 … ] Lifileucel was granted accelerated approval by the FDA on February 16, 2024, for the treatment of unresectable or metastatic melanoma.

    Categories: Antineoplastic cell and gene therapy, Antineoplastic and Immunomodulating Agents
  10. Target

    Mitogen-activated protein kinase kinase kinase 20

    go.drugbank.com/bio_entities/BE0005595
    TargetHumans

    Activates JNK through phosphorylation of MAP2K4/MKK4 and MAP2K7/MKK7, and MAP kinase p38 gamma (MAPK12) via phosphorylation of MAP2K3/MKK3 and MAP2K6/MKK6 (PubMed:11836244, PubMed:12220515). … Acts by catalyzing phosphorylation of MAP kinase kinases, leading to activation of the JNK (MAPK8/JNK1, MAPK9/JNK2 and/or MAPK10/JNK3) and MAP kinase p38 (MAPK11, MAPK12, MAPK13 and/or MAPK14) pathways

    Synonyms: Leucine zipper- and sterile alpha motif-containing kinase, Sterile alpha motif- and leucine zipper-containing kinase AZK